Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 217,273,812 papers from all fields of science
Search
Sign In
Create Free Account
unresectable
Known as:
Non-Resectable
Not capable of being removed by surgery.
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
R. Finn
,
S. Qin
,
+18 authors
A. Cheng
New England Journal of Medicine
2020
Corpus ID: 218633632
BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial…
Expand
Highly Cited
2018
Highly Cited
2018
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
R. Finn
,
S. Qin
,
+17 authors
A. Cheng
The Lancet
2018
Corpus ID: 46813550
Review
2017
Review
2017
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
P. Sharma
,
M. Retz
,
+16 authors
M. Galsky
The Lancet Oncology
2017
Corpus ID: 1934353
Highly Cited
2007
Highly Cited
2007
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
J. Vermorken
,
É. Remenár
,
+15 authors
J. Lefebvre
New England Journal of Medicine
2007
Corpus ID: 8072265
BACKGROUND Phase 2 studies suggest that the standard regimen of cisplatin and fluorouracil (PF) plus docetaxel (TPF) improves…
Expand
Highly Cited
2004
Highly Cited
2004
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
D. Andrews
,
C. Scott
,
+11 authors
W. Curran
The Lancet
2004
Corpus ID: 6391194
Highly Cited
2003
Highly Cited
2003
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
D. Adelstein
,
Yi Li
,
+5 authors
A. Forastiere
Journal of Clinical Oncology
2003
Corpus ID: 24495019
PURPOSE The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to…
Expand
Highly Cited
2002
Highly Cited
2002
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
C. Lo
,
H. Ngan
,
+5 authors
J. Wong
Hepatology
2002
Corpus ID: 5649314
This randomized, controlled trial assessed the efficacy of transarterial Lipiodol (Lipiodol Ultrafluide, Laboratoire Guerbet…
Expand
Highly Cited
2002
Highly Cited
2002
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
J. Llovet
,
M. Real
,
+9 authors
J. Bruix
The Lancet
2002
Corpus ID: 23478234
Highly Cited
1999
Highly Cited
1999
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
K. Furuse
,
M. Fukuoka
,
+5 authors
Y. Ariyoshi
Journal of Clinical Oncology
1999
Corpus ID: 33477028
PURPOSE A phase III study was performed to determine whether concurrent or sequential treatment with radiotherapy (RT) and…
Expand
Review
1996
Review
1996
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.
V. Mazzaferro
,
E. Regalia
,
+7 authors
L. Gennari
New England Journal of Medicine
1996
Corpus ID: 43476102
BACKGROUND The role of orthotopic liver transplantation in the treatment of patients with cirrhosis and hepatocellular carcinoma…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE